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Simple Summary: Cancer-associated fibroblasts (CAFs) are the major cellular component of the tu-
mor microenvironment and have been shown to stimulate tumor growth, epithelial-to-mesenchymal
transition (EMT), invasion, and radio-resistance. Radio-resistance leading to disease relapse is one of
the major challenges in long-term survival and outcome in head and neck squamous cell carcinoma
(HNSCC). Therefore, it is essential to search for predictive markers and new targets for treatment
using clinically relevant in vitro tumor models. We show that CAFs alter the expression of HNSCC
tumor cell genes, many of which are associated with proliferation, differentiation, and metastasis.
Moreover, the expression pattern of selected CAF-regulated genes differed between HNSCC tumor
tissue and the adjacent non-tumoral tissue. Two CAF-regulated genes, MMP9 and FMOD, were found
to be associated with overall survival (OS) in patients treated with radiotherapy.
Abstract: Cancer-associated fibroblasts (CAFs) are known to increase tumor growth and to stim-
ulate invasion and metastasis. Increasing evidence suggests that CAFs mediate response to var-
ious treatments. HNSCC cell lines were co-cultured with their patient-matched CAFs in 2D and
3D in vitro models, and the tumor cell gene expression profiles were investigated by cDNA mi-
croarray and qRT-PCR. The mRNA expression of eight candidate genes was examined in tu-
mor biopsies from 32 HNSCC patients and in five biopsies from normal oral tissue. Differences
in overall survival (OS) were tested with Kaplan–Meier long-rank analysis. Thirteen protein
coding genes were found to be differentially expressed in tumor cells co-cultured with CAFs
in 2D and 81 in 3D when compared to tumor cells cultured without CAFs. Six of these genes
were upregulated both in 2D and 3D (POSTN, GREM1, BGN, COL1A2, COL6A3, and COL1A1).
Moreover, two genes upregulated in 3D, MMP9 and FMOD, were significantly associated with
the OS. In conclusion, we demonstrated in vitro that CAF-derived signals alter the tumor cell
expression of multiple genes, several of which are associated with differentiation, epithelial-to-
mesenchymal transition (EMT) phenotype, and metastasis. Moreover, six of the most highly
upregulated genes were found to be overexpressed in tumor tissue compared to normal tissue.
Cancers 2021, 13, 3361. https://doi.org/10.3390/cancers13133361 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 3361 2 of 16
Keywords: HNSCC; cancer-associated fibroblasts; cDNA microarray; MMP9; FMOD; overall survival
1. Introduction
Cancer of the head and neck is the seventh most common form of cancer worldwide.
About 90% of cases are head and neck squamous cell carcinomas (HNSCC), which have
their origin in the mucosa of the oral cavity, pharynx, larynx, and nasal cavity [1]. The HN-
SCC cancer treatment is primarily based on a combination of surgery and radiotherapy,
but during the last decades, supplementary treatments such as cisplatin-based chemother-
apy and molecular targeted therapy have been introduced. Despite therapy improvements,
the five-year overall survival (OS) in patients with regional metastasis HNSCC has not
changed much and is still less than 50% [2]. Therefore, it is a great need for new therapeutic
strategies and biomarkers that are predictive of the treatment response.
Rather than being understood as malignant cells growing in isolation, cancer has over
the past decades been recognized as a complex tissue where many different cell types
and extracellular matrix interact in a multipart ecosystem. This results in the creation of
a distinct microenvironment within the tumor [3]. One of the most crucial elements of
the microenvironment is the cancer-associated fibroblasts (CAFs). These cells modulate
the tumor’s fate by increasing tumor growth [4], epithelial-to-mesenchymal transition
(EMT) [5], the invasive potential [6], and metastasis [7] by secretion of soluble factors or
by modification of extracellular matrix components [8]. In addition, CAFs have also been
suggested to modulate the drug sensitivity of cancer cells [9,10]. High density of CAF
within the tumor microenvironment is associated with tumor progression and vascular
and perineural invasion that correlate with high rate of local recurrence [11,12]. The role
of CAFs is not fully understood in HNSCC, but different subgroups of CAFs that possess
different properties such as stimulation of Matrigel invasion and tumorigenicity have
been identified [13]. The tumor genetic background may have impact on CAF phenotype,
and genetically unstable tumor cells have been shown to induce senescence in CAFs [14].
Furthermore, CAFs from different patients have been shown to have a different “sensitizing
ratio” for cisplatin response in HNSCC cells in vitro [15].
We have shown earlier that CAFs increase resistance to cetuximab treatment (a mono-
clonal antibody against EGFR; Erbitux®, Merck KGaA) and increase the MMP1 expression
of HNSCC cells during co-culturing compared with tumor cells grown alone in a 2D
model [9]. Recently, we showed that CAFs co-cultured with HNSCC cells in spheroids in-
crease the tumor cell proliferation and have positive impact on the cetuximab and cisplatin
treatment response [16]. A better understanding of the HNSCC microenvironment would
promote the development of more effective treatments. Hence, it is crucial to study how
CAFs influence the gene expression, proliferation, and migration of HNSCC cells.
This study was undertaken to investigate the influence of CAFs on the gene expression
profile of tumor cells in 2D and 3D co-cultures, and furthermore to assess the potential
impact of CAF-regulated genes on radiotherapy response and OS of the patients diagnosed
with HNSCC.
2. Materials and Methods
2.1. Cells and Culture Conditions
Eight HNSCC cell lines—LK0824, LK0858, LK0917, LK0902, LK0923, LK0942, LK0949,
and LK1108 (Table S1)—which were previously established [17] from tissue specimens from
patients diagnosed with HNSCC, were grown in Keratinocyte-SFM supplemented with
antibiotics (50 U/mL of penicillin and 50 µg/mL of streptomycin) and 10% fetal bovine
serum (FBS; all from Gibco, Invitrogen Corporation, Paisly, UK). The cells were given
fresh culture media twice per week and were subcultured at confluence after detaching the
cells with 0.25% trypsin +0.02% EDTA at a weekly split ratio of approximately 1:2 or 1:3.
Cultures from passages 10 to 25 were used in all experiments.
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Eight CAFs were isolated as previously described [9] and originated from the same
eight HNSCC patients as the tumor cell lines listed above. CAFs cultures were grown in
Keratinocyte-SFM supplemented with antibiotics (50 U/mL of penicillin and 50 µg/mL of
streptomycin) and 10% FBS (all from Gibco) and were given fresh media twice per week.
For all experiments, CAFs were used at passages 3–6.
The cells were screened periodically for mycoplasma contamination using the My-
coAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD, USA).
2.2. Co-Culture of Tumor Cells and CAFs
For 2D culturing, tumor cells and CAFs were co-cultured in cell culture flasks for
7 days. Tumor cell and CAF numbers were adjusted so that an approximate ratio of 3:1 was
achieved by the end of co-culture.
As previously described, to achieve spheroids of tumor cells or co-cultures of tumor
cells and CAFs, we seeded 15,000 tumor cells or 10,000 tumor cells with 5000 CAFs into each
well of ultra-low attachment (ULA) 96-well round-bottomed plates (Corning, Amsterdam,
The Netherlands) and were thereafter cultured in standard culture conditions [16].
2.3. Magnetic Activated Cell Sorting (MACS)
Tumor cells grown both in 2D and 3D cultures were separated from CAFs by mag-
netic activated cell sorting (MACS) [16]. RNA was isolated from tumor cells and further
processed for microarray and qPCR analysis (as described below). Tumor cells cultured
without CAFs served as controls.
Cells growing in 2D were incubated with trypsin for 5 min and thereafter flushed in
culture media and then subjected to separation. Spheroids were sampled in a test tube,
centrifuged (1000 rpm, 5 min), washed in PBS, centrifuged, and then incubated with 500 µL
trypsin for 5 to 20 min at 37 ◦C. Thereafter, 1500 µL culture media was added, and the cells
were flushed 30 times with a micropipette and then subjected to separation.
The tumor cells or the tumor cells/CAFs cell suspensions were magnetically labelled
with Anti-fibroblast Micro Beads (Miltenyi Biotech Norden, Lund, Sweden) by a 15-min
incubation at 4 ◦C. The cells were washed, suspended in PBS, and passed through a 50 µm
filter (Becton Dickinson, Franklin Lakes, NJ, USA). The cell suspensions were then loaded
onto MACS® Column Beads (Miltenyi Biotech). The tumor cells were collected in test tubes
placed under the column, and the CAFs were collected in the column due to the magnetic
field. This procedure was repeated three times with each suspension to increase the purity
of each population. To check the purity of the tumor cell suspensions, we cultured cells
for 48 h, and thereafter 500 cells with epithelial or fibroblast morphology were counted in
a phase contrast light microscope. Less than 1% of the cells were found with a fibroblast
morphology in all samples.
2.4. Microarray Analysis
HNSCC cell lines and their patient-matched CAFs were selected for the microarray
analysis in order to compare gene expression differences between tumor cells co-cultured
with patient-matched CAFs and tumor cells cultured alone. Briefly, 2D and 3D microarray
design included in total 5 and 3 biological replicates, respectively. In both cases, multiple
independently derived HNSCC cell lines were treated as biological replicates. Each exper-
imental condition (−CAFs/+CAFs) included a single hybridization of the same sample
where condition was represented by multiple cell lines (n = 5/condition, 2D microarray
design; n = 3/condition, 3D microarray design).Total RNA was prepared using the RNeasy
Mini Kit (Qiagen, Valencia, CA, USA), and the quality was verified using the Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA)and quantified using a
Nanodrop ND-100 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
For the 2D microarray analysis, five HNSCC cell lines (LK0824, LK0858, LK0923,
LK0942, LK0949) and their patient matched CAFs were selected. The labeling and hy-
bridization were done according to the GeneChip® WT Terminal Labeling and Hybridiza-
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tion User Manual for use with the Ambion® WT Expression Kit (Affymetrix, Santa Clara,
CA, USA). The starting amount of total RNA was 100 ng. A total of 15 µg of cRNA was
used for single-stranded cDNA synthesis (sscDNA). A total of 5.5 µg of sscDNA was
fragmented and hybridized on a Human Exon 1.0 ST Array.
For the 3D microarray analysis, three HNSCC cell lines (LK0902, LK0917, and LK1108)
and their patient matched CAFs were selected, and 150 ng of total RNA was used to process
the Affymetrix GeneChip® Human Transcriptome 2.0 Arrays using the GeneChip® WT
Plus Reagent Kit according to the manufacturer’s instructions (Thermo Fisher Scientific,
Waltham, MA, USA). Hybridized arrays were scanned with an Affymetrix GeneChip®
3000 fluorescent scanner.
Microarray data were analyzed with Transcription Analysis Console (TAC) v. 4.0.2.15
(Thermo Fisher Scientific) with default settings. Briefly, the SST-RMA was used for nor-
malization of the 3D microarray data and RMA for normalization of 2D microarray data.
Differential expression analysis was carried out with Limma package in TAC with a
paired design. Probesets with the detected above background (DABG) value < 0.05 in
less than half of samples were not considered. Gene fold change <−2 or >2 were consid-
ered differentially expressed. Heatmaps were generated with a freely available online
application Heatmapper [18]. Description of samples subjected to microarray analysis
is provided in Tables S3 and S4. The data have been deposited at Gene Expression Om-
nibus (http://www.ncbi.nlm.nih.gov/geo/ (accessed on 15 June 2021)) database under the
accession numbers GSE178153 and GSE178154.
2.5. qRT-PCR
The qRT-PCR analysis was performed on a 7500 Fast Real-Time PCR system (Applied
Biosystems, Waltham, MA, USA). Total RNA was extracted from cells using the RNeasy
Mini Kit (Qiagen, Hilden, Germany), cDNA was synthesized using the High-Capacity RNA-
to-cDNA Kit (Applied Biosystems), and TaqMan FAM/MGB probes (Applied Biosystems)
were used for PCR reactions. Amplification of two housekeeping genes, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and ß-actin, was used as an internal standard.
The data were calculated according to the comparative Ct method to present the data as
fold differences in the expression levels relative to the control sample [19].
2.6. Immunohistochemistry (IHC)
Spheroids were fixed in 4% paraformaldehyde (Santa Cruz Biotechnology, Dallas,
TX, USA) overnight at 4 ◦C followed by rinsing with PBS, stained with 0.1% toluidine
blue D (Merck, Kenilworth, NJ, USA) and centrifuged in 2% agarose. Agarose blocks
containing spheroids were dehydrated and thereafter embedded in paraffin wax (Merck,
Kenilworth, NJ, USA). Sections of 5 µm were collected on Super Frost Plus slides (Thermo
Fisher Scientific, Fremont, CA, USA), dried overnight, and then incubated at 58 ◦C for
1 h. Sections were deparaffinized in Histolab-Clear (HistoLab, Gothenburg, Sweden),
re-hydrated in graded alcohols, underwent antigen retrieval (PT 200, DAKO, Glostrup,
Denmark A/S), and were then blocked for endogenous peroxidase activity in 3% peroxidase
(Sigma-Aldrich, St. Louis, MO, USA). After incubation in blocking buffer (0.1% BSA-5% FBS
in TBS-Triton), sections were incubated overnight at 4 ◦C with primary antibodies: MMP1
(1:50; Abcam, Cambridge, UK), MMP9 (1:500, Abcam), gremlin (1:100, Abcam), periostin
(1:50), Abcam), and fibromodulin (1:50; Invitrogen, Carlsbad, CA, USA). Thereafter, sections
were washed in TBS-triton buffer and incubated with a goat anti-rabbit or a goat-anti-mouse
HRP-antibody (1:500; IgG, EMD Millipore Corporation, Temecula, CA, USA) for 60 min at
room temperature. Following the washing steps, slides were developed for 6 min using the
ImmPACT NovaRED peroxidase substrate kit at room temperature (Vector Laboratories,
Burlingame, CA, USA). Thereafter, sections were counterstained in Mayer’s hematoxylin
(HistoLab) for 4 min, dehydrated, cleared in Histolab-Clear, and cover slipped with Pertex
(HistoLab). As negative controls sections were stained as above described but without the
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primary antibody. All negative controls were revealed unstained. Images were acquired
with a light microscope (Olympus BX51, Shinjuku City, Tokyo, Japan) with a 20× objective.
2.7. Tumor Material and Patient Characteristics
Samples from patients with HNSCC were obtained from an established tumor collec-
tion (No 416, The National Board of Health and Welfare in Sweden) at the Department of
Otorhinolaryngology, Head and Neck Surgery, at the University Hospital of Linköping,
Sweden (approved by the Ethical Committee of Linköping). The collection consists of ap-
proximately 350 tumor biopsies, freshly obtained at the time of surgery after obtaining due
consent from the patients. Tumor and CAFs cell lines were established from one part of pre-
treatment biopsies [17]: one part of the biopsy was immediately frozen in liquid nitrogen
and stored in−70 ◦C, and the third part was formalin-fixed and paraffin-embedded. For all
samples, clinical and follow-up data of the patients were available from the Department of
Otorhinolaryngology.
All patients included received radiotherapy as follows: 13 (40.6%) received radiother-
apy alone, 15 (46.9%) received preoperative radiotherapy, 3 (9.4%) received postoperative
radiotherapy, and 1 (3.1%) received chemotherapy in addition to radiotherapy. Patients
were retrospectively divided into two groups according to treatment response. A patient
was considered as a responder if the tumor size was reduced during radiotherapy and
no sign of recurrent disease was noted within one year following radiation. In the non-
responder group, tumors either grew during on-going radiation or patients were diagnosed
with relapse of disease within 6 months of radiotherapy. Sixteen individuals were identified
as non-responder, whereafter sixteen responders were selected and matched according to
tumor localization and histological grade as closely as possible (Table S2). The distribution
of patients according to TNM classification (according to the general rules of head and
neck cancer), histological grade, sex, and age has earlier been published [20]. Non-tumoral
biopsies were collected from the sites as far as possible from the tumor margin.
2.8. Statistical Analysis
Statistical analyses were performed with Prism 7.0 (GraphPad Software, Inc., La Jolla,
CA, USA) and SPSS IBM version 26.0 (IBM Corporation, Armonk, NY, USA). All values
obtained were represented as mean± SD of at least three independent experiments. For the
verification of microarray in HNSCC cell lines, log2 mRNA expression levels were analyzed
using unpaired two-tailed Student’s t-test. One-way ANOVA followed by post-hoc Tukey’s
multiple correction test was applied to analyze the patient data. The mRNA expression
results of selected genes were analyzed for correlation with OS using the Kaplan–Meier
survival analysis with log-rank test. The relationship between mRNA expression in tumor
tissue and treatment response was assessed by binary logistic regression. The high and
low mRNA levels were assessed on the basis of the median mRNA expression. All values
obtained were represented as mean ± SD of at least three independent experiments.
3. Results
3.1. Microarray Analysis in 2D Cultures
Five HNSCC cell lines (LK0824, LK0858, LK0923, LK0942, and LK0949; Table S1) were
co-cultured in 2D with their patient matched CAFs for seven days. CAFs were distributed
around tumor cell colonies in a similar pattern as observed in patient derived tumor
samples (Figure 1A). Tumor cells cultured without CAFs served as controls (Figure 1B).
Tumor cells were separated from CAFs by MACS, and the purity of the tumor cell cultures
were verified by microscopy. The gene expression of the five HNSCC cell lines co-cultured
with or without their patient matched CAFs was investigated by microarray analysis.
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THBS1 ↑ 7.51 SYTL2 ↓ −2.32 SCEL ↓ −6.66
GREM1 ↑ 6.67 CRABP2 ↓ −2.31 SPRR1A ↓ −6.52
AMTN ↑ 6.39 FRK ↓ −2.3 CES1 ↓ −5.43
SPARC ↑ 6.19 TMPRSS4 ↓ −2.27 MIR203A ↓ −5.06
EMP3 ↑ 5.51 CYP4F3 ↓ −2.19 OCLN ↓ −4.45
CTSK ↑ 3.84 TLR6 ↓ −2.16 KLK10 ↓ −4.15
↑ upregulated, ↓ downregulated.
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3.2. Microarray Analysis in 3D Cultures
Recently, we have developed a unique tumor experimental in vitro model that consists
of low-passage HNSCC cells (LK0902, LK0917, and LK1108) and CAFs from the same tumor
growing in spheroids. In this in vitro model, CAFs affect proliferation; EGFR expression;
and, to some extent, the EMT and cancer stem cell phenotype of HNSCC tumor cells [16].
Here, we used this biologically relevant in vitro model and investigated which tumor
genes are affected by CAFs. Three HNSCC cell lines (LK0902, LK0917, and LK1108) were
co-cultured in spheroids with their patient-matched CAFs for five days. Thereafter, tumor
cells were separated from CAFs by MACS, and the purity of the tumor cell cultures were
verified by microscopy. The gene expression profiles in the three HNSCC cell lines co-
cultured with or without their patient matched CAFs was investigated by microarray
analysis.
In tumor cells co-cultured with CAFs, 164 genes were upregulated while 169 genes
were downregulated (Table 1 and Table S4, Figures S6 and S7) compared to tumor cells
grown without CAFs. Similar to the 2D experiment, expression differences were associated
with a relatively large cell line to cell line variability and calling relied on the fold-change
cut-offs. Interestingly, six genes—POSTN, GREM1, BGN, COL1A2, COL6A3, and COL1A1—
that were found to be upregulated in 2D cultures were also upregulated in spheroids.
In contrast, no shared downregulated genes were found between 2D and 3D cultures.
3.3. Verification of Microarray Results Using qRT-PCR
Verification of microarray results was performed using qRT-PCR. Three of the differen-
tially expressed protein coding genes (COL1A2, GREM1, and POSTN) revealed by microar-
ray analyses in 2D cultures were analyzed. The analysis verified a change in expression of
COL1A2, GREM1, and POSTN upon co-culture with CAFs (Figure 2A). The expression of
GREM1 and COL1A2 could not be detected in LK0824, LK0858, or LK0923 tumor mono-
cultures by qRT-PCR; thus, the Ct-values were set to 40 in order to enable fold-change
calculations using the comparative Ct method.
Moreover, 10 of the differentially expressed protein coding genes (MMP1, MMP9,
COL1A2, GREM1, POSTN, FMOD, THSB, DCN, VCAN, CTSK, and IVL) revealed by mi-
croarray analysis of tumor cells cultured in spheroids were selected for verification by
qRT-PCR. The analysis verified a significant upregulation of MMP9, MMP1, COL1A2,
GREM1, POSTN, FMOD, DCN, THSB1, and VCAN mRNA expression in all cell lines upon
co-culture with CAFs. Furthermore, CTSK was upregulated in two of the cell lines, and IVL
was found highly downregulated in all cell lines (Figure 2B–D).
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IVL was found highly downregulated in all cell lines (Figure 2B–D). 
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To further verify the microarray results, the protein expression of MMP9, MMP1, 
periostin, gremlin 1, and fibromodulin were investigated in spheroids with immunohisto-
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tured with CAFs compared to tumor cells cultured alone in spheroids (Figure 3 and Figure 
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Figure 2. Verification of microarray with qRT-PCR. Five head and neck squamous cell carcinoma cell
lines (LK0824, LK0858, LK0923, LK0942, LK0949) were grown alone or co-cultured with their patient-
matched canc r-asso iated fibroblasts (CAFs) as 2D monolayers f r 7 days. RNA was isolated from
tumor cells (sepa at d from CAFs by magnetic activated c ll sorting) and the mRNA expression of the
COL1A2, GREM1, and POSTN genes, which, by microarray analysis, were identified as differentially
expressed in co-cultures, was analyzed by qRT-PCR. The log2 mRNA levels of co-cultured tumor cells
are shown relative to the expression in tumor cells grown alone (A). Three head and neck squamous
cell carcinoma cell lines were grown in spheroids alone or co-cultured with their patient-matched
cancer-associated fibroblasts (CAFs) for 5 days. RNA was isolated from tumor cells (separated from
CAFs by magnetic activated cell sorting) and the mRNA expression of the MMP1, MMP9, POSTN,
GREM1, COL1A2, FMOD, DCN, THBS1, VCAN, CTSK, and IVL genes, which, by microarray analysis,
were identified as differentially expressed in co-cultures, was analyzed by qRT-PCR. The log2 mRNA
levels of co-cultured tum r cells are shown relativ to the expr ssi n in tumor cells grown alone
(B–D). Data were normalized to cells cultured without CAFs for each gene (mean values ± SD; n = 3).
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 according to Student’s t-test.
3.4. Verification of Microarray Resul s on Protein L vel
To further verify the microarray results, the protein expression of MMP9, MMP1,
periostin, gremlin 1, and fibromod lin were investigated in spheroids with immunohisto-
chemistry (IHC). MMP1 was found to be upregulated in ll three cell lines when co-cultured
with CAFs compared to tumor cells cultured alone in sph roids (Figure 3 and Figure S1).
MMP9 was upregulated in LK0902 and LK0917 tumor cells/CAFs spheroids, but in LK1108,
only a few cells were positively st ined for MMP9 (Figure 3 and Figure S2). Periostin and
gremlin showed a weak to moderate staining in tumor cell/CAF spheroids compared to
tumor cell spheroids (Figure 4, Figures S3 and S4). Moreover, fibromodulin showed a
moderate staining in LK0902 and LK1108 in tumor cell/CAF spheroids compared to tumor
cell spheroids (Figure 4 and Figure S5). Despite the moderate staining of fibro odulin in
LK0917 tumor spheroids, a relatively stronger staining was observed in tumor cell/CAF
spheroids (Figure 4 and Figure S5).
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3.5. Expression of CAF-Regulated Genes in Tumor Tissue and Their Impact on
Radiotherapy Response
To determine the significance of CAF-regulated genes in HNSCC, we analyzed the
mRNA expression of most dysregulated genes including MMP1, MMP9, POSTN, GREM1,
FMOD, COL1A2, GREM1, IVL, and α-SMA (a CAF marker) in two groups of HNSCC
patients (responders or non-responders to radiotherapy) and in five biopsies from adjacent
normal oral tissue.
Our results show a significantly higher mRNA expression of MMP1, MMP9, POSTN,
GREM1, FMOD, and COL1A2 in tumor biopsies compared to normal tissue (Figure 5),
but the significant difference between responder and non-responder groups was only
found for the expression of FMOD mRNA. The expression of α-SMA was higher in the
HNSCC biopsies than in adjacent normal oral tissue reaching the statistical significance in
the responder group.




Figure 5. Validation of selected CAF-regulated mRNA candidates in biopsies obtained from patients diagnosed with 
HNSCC. RNA was isolated from tumor tissue (17 responders, 16 non-responders) and normal oral tissue (n = 5) and the 
mRNA expression of the MMP1, MMP9, POSTN, GREM1, COL1A2, FMOD, and IVL genes, which, by microarray analysis, 
were identified as differentially expressed in co-cultures, was analyzed by qRT-PCR. The CAF marker such as α-SMA was 
also included in the analysis. The log2 mRNA levels of tumor tissue are shown relative to the expression in normal oral 
tissue. Data are shown as mean values ± SD; n = 3. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Abbreviations: N, adjacent normal 
oral tissue; NR, non-responder; R, responder. 
We next tested whether mRNA levels of analyzed genes correlate with OS of HNSCC 
patients. Patients with high expression of MMP9 mRNA had significantly longer OS com-
pared to the low expression group (p = 0.011; Figure 6A). Like MMP9, patients with high 
expression of FMOD mRNA had significantly longer OS compared with those who had 
low expression of FMOD mRNA (p = 0.026; Figure 6B). Moreover, the combination of high 
expression of both MMP9 and FMOD mRNA was associated with significantly longer OS 
compared to low and/or high expression of either MMP9 or FMOD in the analyzed cohort 
(p = 0.017; Figure 6C). There was a trend towards a longer OS for patients expressing a 
high level of IVL mRNA (p = 0.33; Figure 6D). 
Figure 5. Validation of selected CAF-regulated mRNA candidates in biopsies obtained from patients diagnosed with
HNSCC. RNA was isolated from tumor tissue (17 responders, 16 non-responders) and normal oral tissue (n = 5) and the
mRNA expression of the MMP1, MMP9, POSTN, GREM1, COL1A2, FMOD, and IVL genes, which, by microarray analysis,
were identified as differentially expressed in co-cultures, was analyzed by qRT-PCR. The CAF marker such as α-SMA was
also included in the analysis. The log2 mRNA levels of tumor tissue are shown relative to the expression in normal oral
tissue. Data are shown as mean values ± SD; n = 3. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Abbreviations: N, adjacent normal
oral tissue; NR, non-responder; R, responder.
We next tested whether mRNA levels of analyzed genes correlate with OS of HNSCC
patients. Patients with high expression of MMP9 mRNA had significantly longer OS
compared to the low expression group (p = 0.011; Figure 6A). Like MMP9, patients with
high expression of FMOD mRNA had significantly longer OS compared with those who
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had low expression of FMOD mRNA (p = 0.026; Figure 6B). Moreover, the combination of
high expression of both MMP9 and FMOD mRNA was associated with significantly longer
OS compared to low and/or high expression of either MMP9 or FMOD in the analyzed
cohort (p = 0.017; Figure 6C). There was a trend towards a longer OS for patients expressing
a high level of IVL mRNA (p = 0.33; Figure 6D).




Figure 6. Kaplan–Meier log-rank survival analysis of HNSCC patients with regard to different mRNA expressions. (A) 
MMP9; (B) FMOD; (C) MMP9/FMOD; (D) IVL. 
4. Discussion 
For many years, cancer research has focused mainly on the cancer cell and its molec-
ular changes; however, the stromal microenvironment is now generally accepted to mod-
ulate the tumor’s fate by increasing tumor growth (9–11), the invasive potential (14,15), 
and metastasis (12–16) by secretion of soluble factors or by modification of extracellular 
matrix components (17). The molecular mechanisms behind these CAF-induced changes 
in the tumor cell phenotype are complex and still not fully understood. 
In this study, we investigated the influence of CAFs on the gene expression of five 
HNSCC cell lines growing in 2D and in three HNSCC cell lines growing in 3D. One of the 
strengths of our experimental plan lies in the use of several patient matched HNSCC cell 
lines and CAFs. The two cell types were grown in co-cultures allowing cell–cell contact 
both in 2D and 3D, which mimics the in vivo situation but to a higher extent in 3D. In this 
way, the crosstalk between tumor cells and CAFs can be closely monitored without the 
influence of other cell types present within the tumor microenvironment. By whole-ge-
nome microarray analysis, we were able to identify multiple genes that were differentially 
expressed in across multiple HNSCC cell lines co-cultured with CAFs as compared to 
monocultures. 
Six genes (POSTN, GREM1, BGN, COL1A2, COL6A3, and COL1A1) were upregulated 
in both the 2D and 3D model. Recently it was published that 10 HUB genes (SPP1, POSTN, 
COL1A2, FN1, IGFBP3, APP, MMP3, MMP13, CXCL8, and CXCL12) were differentially 
expressed in HNSCC [21]. In one of our previous studies, FN1 was found to be upregu-
lated in two of the investigated cell lines [16]. In the present study, POSTN and COL1A2 
were upregulated in all cell lines after coculture with CAFs. It has been reported that 
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4. Discussion
For many years, cancer research has focused mainly on the cancer cell and its molecu-
lar changes; however, the stromal microenvironment is now generally accepted to mod-
ulate the tumor’s fate by increasing tumor growth [9–11], the invasive potential [14,15],
and metastasis [12–16] by secretion of soluble factors or by modification of extracellular
matrix components [17]. The molecular mechanisms behind these CAF-induced changes
in the tumor cell phenotype are complex and still not fully understood.
In this study, we investigated the influence of CAFs on the gene expression of five
HNSCC cell lines growing in 2D and in three HNSCC cell lines growing in 3D. One of
the strengths of our experimental plan lies in the use of several patient matched HNSCC
cell lines and CAFs. The two cell types were grown in co-cultures allowing cell–cell
contact both in 2D and 3D, which mimics the in vivo situation but to a higher extent in
3D. In this way, the crosstalk between tumor cells and CAFs can be closely monitored
without the influence of other cell types present within the tumor icroenvironment.
By whole-genome microarray analysis, we were able to identify multiple genes that were
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differentially expressed in across multiple HNSCC cell lines co-cultured with CAFs as
compared to monocultures.
Six genes (POSTN, GREM1, BGN, COL1A2, COL6A3, and COL1A1) were upregulated
in both the 2D and 3D model. Recently it was published that 10 HUB genes (SPP1, POSTN,
COL1A2, FN1, IGFBP3, APP, MMP3, MMP13, CXCL8, and CXCL12) were differentially
expressed in HNSCC [21]. In one of our previous studies, FN1 was found to be upregulated
in two of the investigated cell lines [16]. In the present study, POSTN and COL1A2 were
upregulated in all cell lines after coculture with CAFs. It has been reported that COL1A1
and COL1A2 are both overexpressed in gastric cancer, and a high COL1A1 and COL1A2
mRNA expression was suggested to be a prognostic factor predicting OS [22]. Furthermore,
COL1A2 has been suggested to be a regulator of pancreatic cancer [23]. In the present study,
we found six members of the collagen family to be upregulated tumor cells co-cultured
with CAFs. Two of these were from the type I collagen group, which are mostly found
in connective tissue and embryonic tissue [24], and are key structural components of the
extracellular matrix.
When investigating the mRNA expression of COL1A2, POSTN, GREM1, MMP1,
and MMP9 in patient material, we found all five genes to be upregulated in HNSCC tumor
tissue compared to normal oral tissue. Periostin (POSTN) is a protein ligand to trans-
membrane receptors called integrins. Integrins are important in adhesion between cells
and between cells and extracellular matrix in tissue. Upregulation of periostin has been
observed in a wide variety of cancers including colon, gastric, and esophageal cancer [25].
Gremlin-1 (GREM1) is a member of the cystine knot superfamily and is a bone morpho-
genetic protein (BMP) antagonist. BMPs play a critical role in embryogenesis, development,
tissue differentiation, and regulation of the immune system [26]. GREM1 is thought to be
involved in EMT [27] and has been shown to be overexpressed in human tumors, including
carcinomas of the colon and lung [28,29]. In breast cancer, GREM1 was shown to be an
oncogenic protein by promoting tumor cell proliferation, migration, and invasion, which is
associated with worsening of survival. Moreover, knock-down of GREM1 was found to
result in decreased proliferation of breast cancer cells [30].
Matrix metalloproteinases (MMPs), which are known to degrade the extracellular ma-
trix, have been suggested as strong mediators of cancer invasion and metastasis. MMPs are
thought to regulate cancer cell growth, apoptosis, and angiogenesis by releasing bioactive
fragments, and increased expression of MMPs has been shown to result in poor clinical
outcome in several cancer types [31–33]. In a previous study, we demonstrated that MMP1
was upregulated in HNSCC cells when cocultured with CAFs in a 2D model and that
MMPs were involved in cetuximab resistance [9]. In spheroids, MMP1 and MMP9 showed
the highest level of overexpression on the mRNA level and were found to be upregulated
also at protein level using IHC. MMP1 was earlier shown to be upregulated in HNSCC
tissue [34] and was positively associated with lymph node metastasis (LNM) [35,36]. More-
over, high expression of MMP9 has been reported to correlate to LNM, angiogenesis,
and worse survival in HNSCC [37,38]. MMP1 and MMP9 were not upregulated in tumor
cells co-cultured with CAFs in 2D, but these MMPs were upregulated in tumor tissue from
HNSCC patients compared to normal oral tissue. These results indicate that that our 3D
in vitro model is more similar to tumor tissue than our 2D model and that the upregulation
of these MMPs is cell adhesion dependent. Surprisingly, in this study, patients with a high
mRNA expression of MMP9 had a significant better survival compared with patients with
a low expression (Figure 6A). The role of MMPs in cancers is more complex than previously
thought. More than 50 MMP inhibitors have been investigated in various cancers, but all
have failed [39], and in a study consisting of 37 HNSCC patients treated with cisplatin and
cetuximab, a high mRNA expression of MMP9 was associated with objective treatment
response [40]. However, the impact of MMP9 as a predictive biomarker for radiotherapy
response need to be further evaluated.
The small leucine-rich proteoglycan decorin (DCN) is an important component of the
cellular microenvironment and has been shown to inhibit the growth of a wide variety
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of tumor cells, probably due to an interaction of the decorin core protein with EGFR [41].
Another small leucine-rich proteoglycan, fibromodulin (FMOD), was also upregulated at
transcript level in tumor cells after coculturing with CAFs. Fibromodulin has been shown
to affect biological processes such as angiogenesis, apoptosis, and migration, and exerts its
effects via targeting certain signaling pathways such as TGF-β [42]. FMOD has been recog-
nized as a novel tumor-associated antigen in lymphoma, leiomyoma, and leukemia [43],
and FMOD has been detected in various clinical malignancies, such as breast, prostate,
and lung carcinomas [44–46]. In this study, patients in the responder group had a signifi-
cant higher expression of FMOD (Figure 5), and patients with a higher mRNA expression
of FMOD had a significantly better survival compared with patients with a low expression
(Figure 6B). The role of fibromodulin and decorin for radiotherapy response in HNSCC is
still unknown, but in a breast cancer cell line, 4T1, overexpression of FMOD and DCN was
associated with downregulation of NF-κB and TGF-β1 [47]. Activation of nuclear factor-κB
(NF-κB) has been shown to inhibit apoptosis and to stimulate proliferation [48]. Further-
more, NF-κB signaling has also been shown to be essential for epithelial–mesenchymal
transition and metastasis [49]. One theory for the higher survival rate observed in patients
with a high FMOD expression could relate to an effect of FMOD on NF-κB and TGF-β1,
but this has to be further investigated.
Several genes associated with cornified squamous epithelia and terminal differentia-
tion were found to be downregulated in tumor cells cocultured with CAFs. One of them,
sciellin, a precursor of the cornified envelope, has been found to mediate mesenchymal-
to-epithelial transition and knockdown of sciellin increase invasion and migration of
colorectal cancer cells [50]. IVL (involucrin) was the most downregulated gene in the 3D
model and was found to be downregulated in most of the tumor samples. Involucrin
has earlier been suggested as a promising marker of tumor differentiation and survival in
squamous carcinoma of the larynx [51]. In this study, we found a trend towards a better
OS for patients expressing high IVL. High expression of α-SMA has been proposed as a
marker for activated fibroblasts, and a higher expression of α-SMA has been shown in
CAFs compared to normal fibroblasts [52]. However, during the last years, there has been
published data showing different populations of CAFs with different properties and with
different expression of for example α-SMA and BMP4 [53,54]. In this study, we found a
higher expression of α-SMA in the HNSCC biopsies than in non-cancerous oral tissue.
The role of CAFs for progression and treatment response of HNSCC is still unclear.
The impact of fibroblasts for radiation response largely depends on the combination of
fibroblast and tumor cell type, and the same fibroblast type has been shown to either
decrease or increase the radiation response in different cancer cell lines [55]. Furthermore,
it has been shown that cisplatin response in FaDu cells was CAF-specific when CAFs from
seven different HNSCC patients were tested in a 2D model [15]. Our results show that
two proteins upregulated of CAFs, FMOD and MMP9, have a positive impact on OS with
regard to radiotherapy; however, due to the small amount of patient material, this has
to be further investigated. An increased understanding of the crosstalk between cancer
cells and CAFs is of critical importance, as it can lead to the design of new strategies in
the treatment of HNSCC. Therefore, we investigated which genes were affected by their
patient matched CAFs in a 2D co-culture model and in a more biologically relevant 3D
in vitro model. The pattern of CAF localization within the spheroids can have impact
on paracrine signaling, which resembles the tumor microenvironment better. Moreover,
CAF-mediated remodeling of extracellular matrix in our 3D model manifests with higher
expression of collagen and MMPs as compared to 2D model. Interestingly, two of the genes,
MMP9 and FMOD, that both were upregulated in tumor cell/CAF spheroids compared
to tumor spheroids were found to have a positive impact on overall survival in HNSCC
patients. In our recent study, we showed that CAFs increased proliferation and sensitivity
to cisplatin in two of three HNSCC cell lines in 3D co-cultures [16]. One explanation could
be due on the rationale that the rapidly proliferating cancer cells are more sensitive to
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DNA-damaging treatment such as ionizing radiation and cisplatin treatment than cells
with lower proliferation rate [56].
5. Conclusions
In summary, by co-culture of HNSCC cell lines with their patient-matched CAF,
the expression of multiple genes was found to be regulated by CAF-derived signals.
Moreover, the most changed genes were also found to be differentially expressed in tumor
tissue compared to normal oral tissue.
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